Loading provider…
Loading provider…
Infectious Disease Physician in Newport Beach, CA
NPI: 1205810066Primary Practice Location
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
16200 Sand Canyon Ave, Irvine, CA
Primary Employer
Hoag Hospital Newport Beach
hoag.org
HQ Phone
Get MD Philip's Phone Numberphone_androidMobile
Get MD Philip's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1991 - 2027
MI State Medical License
1995 - 1999

American Board of Internal Medicine
Infectious Disease
College of Human Medicine - Grand Rapids
humanmedicine.msu.edu
Medical School
Until 1990
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Fellowship • Infectious Disease
1993 - 1995
Los Angeles County-Harbor-UCLA Medical Center
Residency • Internal Medicine
1990 - 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 14 | 41 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 14 | 14 |
Authors: Adu, Jimi, Leong, Fong T, Smith, Neil R, Leek, Jack P, Markham, Alexander F, Robinson, Philip A, Mighell, Alan J
Journal: Gene Expr Patterns
Authors: @ValidYN, LastName, ForeName, Initials, Identifier, AffiliationInfo
Journal: Vet Rec
Publication Date: 2019-08-22
Authors: Barry Meisenberg, David Park, Phillip Scheinberg, Priti Patel, Matt Khoshnevis
Journal: Immunohorizons
Lead Sponsor: ImmunityBio, Inc.
Intervention / Treatment: BIOLOGICAL: hAd5-S-Fusion+N-ETSD (Suspension for injection), DRUG: hAd5-SFusion+ N-ETSD (Oral capsule)
Lead Sponsor: University of California, Irvine
Collaborators: Agency for Healthcare Research and Quality (AHRQ)
Intervention / Treatment: BEHAVIORAL: Standard-of-Care Education, DRUG: MRSA Decolonization
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib